- Home
- COCH vs TPST Comparison
COCH vs TPST Comparison
Compare COCH & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COCH
- TPST
- Stock Information
- Founded
- COCH 1995
- TPST 2011
- Country
- COCH United States
- TPST United States
- Employees
- COCH N/A
- TPST N/A
- Industry
- COCH Blank Checks
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- COCH Finance
- TPST Health Care
- Exchange
- COCH Nasdaq
- TPST Nasdaq
- Market Cap
- COCH 29.8M
- TPST 27.2M
- IPO Year
- COCH N/A
- TPST N/A
- Fundamental
- Price
- COCH $1.41
- TPST $0.93
- Analyst Decision
- COCH Strong Buy
- TPST Strong Buy
- Analyst Count
- COCH 3
- TPST 4
- Target Price
- COCH $8.00
- TPST $20.00
- AVG Volume (30 Days)
- COCH 54.8K
- TPST 1.8M
- Earning Date
- COCH 11-14-2024
- TPST 11-12-2024
- Dividend Yield
- COCH N/A
- TPST N/A
- EPS Growth
- COCH N/A
- TPST N/A
- EPS
- COCH N/A
- TPST N/A
- Revenue
- COCH $278,000.00
- TPST N/A
- Revenue This Year
- COCH N/A
- TPST N/A
- Revenue Next Year
- COCH $19.76
- TPST N/A
- P/E Ratio
- COCH N/A
- TPST N/A
- Revenue Growth
- COCH 15.35
- TPST N/A
- 52 Week Low
- COCH $1.08
- TPST $0.70
- 52 Week High
- COCH $11.46
- TPST $6.00
- Technical
- Relative Strength Index (RSI)
- COCH 38.92
- TPST 54.03
- Support Level
- COCH $1.21
- TPST $0.86
- Resistance Level
- COCH $1.50
- TPST $1.05
- Average True Range (ATR)
- COCH 0.20
- TPST 0.08
- MACD
- COCH 0.01
- TPST 0.01
- Stochastic Oscillator
- COCH 32.26
- TPST 52.92
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing innovative medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.